Jose Luis Ramirez

TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.

TL;DR: The study of serum or plasma DNA has opened new roads for translational research and new strategies for molecular diagnosis and can be used to calculate the risk of local or distant recurrence and its relationship with survival and its value in patient follow-up to evaluate response to therapy.

TL;DR: Analysis of the outcome of second-line chemotherapy or EGFR TKIs in 179 of 366 patients who had been treated in an ERCC1 mRNA-based customized cisplatin trial and correlated the results with CHFR methylation status found that unmethylated CHFR predicts increased survival to EGFRTKIs.

TL;DR: Serum-based MGMT methylation analysis offers a promising alternative to tumor- based MGMT analysis in cases where tissue samples are unavailable and patients whose MGMT promoter was methylated in tissue attained longer progression-free and overall survival.

TL;DR: The combination of bevacizumab plus temozolomide is more active than temozalomide alone and may well confer benefit in terms of tumor shrinkage in unresected patients albeit at the expense of greater toxicity.